Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.

Author: ChuXudong, JiQinghua, LiuXuan, YeWei, ZhaoWei, ZhouYugui

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Grazoprevir/elbasvir (GZR/EBR) treatment showed high efficacy and safety in hemodialysis-dependent patients with genotype 1b acute hepatitis C (AHC). All 68 patients achieved sustained virologic response at 12 weeks after treatment cessation. The most common adverse events were fatigue, headache, and nausea.
Paper Details　
Original Abstract of the Article :
Treatment of hepatitis C virus (HCV) infection with direct-acting antiviral agents (DAAs) in hemodialysis patients requires extensive consideration. At present, studies regarding DAAs for acute HCV infection in such patients are limited. The present study aims to evaluate the efficacy and safety of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298284/

データ提供：米国国立医学図書館（NLM）

Grazoprevir/Elbasvir: A Promising Treatment for Acute Hepatitis C in Hemodialysis Patients

Hepatitis C virus (HCV) infection is a significant global health concern, particularly among individuals undergoing hemodialysis. Treatment of HCV infection in this population presents unique challenges. This research evaluates the efficacy and safety of grazoprevir (GZR) plus elbasvir (EBR) treatment for acute hepatitis C (AHC) in hemodialysis patients. The study aims to determine the effectiveness of this direct-acting antiviral agent (DAA) combination in achieving sustained virologic response (SVR12) and assess the safety profile in this vulnerable patient group.

A New Hope for Acute Hepatitis C Treatment in Hemodialysis Patients

The study found that GZR/EBR demonstrated high efficacy in achieving SVR12 in all patients enrolled, who were infected with HCV genotype 1b. This positive outcome underscores the potential of this DAA combination in treating AHC in hemodialysis patients. This research offers a ray of hope for individuals undergoing hemodialysis who are diagnosed with HCV infection, providing a promising treatment option to combat this debilitating disease.

Managing HCV Infection in Hemodialysis Patients: A Step Forward

This study provides valuable information for healthcare professionals managing HCV infection in hemodialysis patients. The findings suggest that GZR/EBR is a safe and effective treatment option for AHC in this population. This research underscores the importance of exploring and implementing effective treatment strategies to improve the health and well-being of individuals with HCV infection, particularly in the context of hemodialysis. Just as a desert traveler seeks a reliable source of water, finding effective treatments for HCV infection in hemodialysis patients is crucial for their health journey.

Dr.Camel's Conclusion

This study demonstrates the high efficacy and safety of GZR/EBR in treating genotype 1b AHC in hemodialysis patients. The findings provide valuable insights into the management of HCV infection in this vulnerable population, offering a promising treatment option to combat this debilitating disease. This research highlights the importance of ongoing research and development in the field of HCV treatment, particularly for individuals undergoing hemodialysis.

Date :
  1. Date Completed 2022-02-08
  2. Date Revised 2022-07-31
Further Info :

Pubmed ID

34599755

DOI: Digital Object Identifier

PMC9298284

Related Literature

Article Analysis
・Effects of elbasvir and grazoprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.